Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair

TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.

Subsidie
€ 150.000
2023

Projectdetails

Introduction

More than 3.5 million people are newly diagnosed with heart failure every year in Europe, with a long-term prognosis of 50% mortality within 4 years. There is a major need for more innovative, regenerative therapies that have the potential to change the course of the disease.

Project Overview

In the ERC-Extracellular Vesicle-Inspired CArdiac REpair (EVICARE), I hypothesized that we can recondition heart failure by stimulating cardiac repair with extracellular vesicles that are derived from progenitor cells. From the EVICARE application results, however, we realized that enhancing the therapeutic load of EVs will enhance their functional effect size to treat chronic diseases.

In TOP-EVICARE (Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair), I aim to explore active loading and release systems that will allow protein therapeutic loading in extracellular vesicles to stimulate myocardial repair.

Project Objectives

Within this project, I aim to:

  1. Validate our innovative EV-loading strategy by assessing biodistribution and functional delivery in vivo, and exploring the potential for upscaling GMP production to meet industry standards and requirements.
  2. Conduct a comprehensive intellectual property (IP) landscape analysis to establish freedom-to-operate (FTO) and ensure that our technology can be commercialized without infringing on existing patents.
  3. Execute an in-depth market, competitor, and stakeholder analysis to identify strategic opportunities and potential challenges in the EV-based therapeutic landscape.
  4. Develop a robust and detailed business plan to effectively guide the commercialization of our loading technology, thus bringing a transformative solution to the treatment of various diseases.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-10-2023
Einddatum31-3-2025
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITAIR MEDISCH CENTRUM UTRECHTpenvoerder

Land(en)

Netherlands

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration

Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.

€ 1.592.281
ERC Proof of...

Reliable and scalable procedures for the isolation and loading of extracellular vesicles

LABORIOUS aims to develop innovative methods for isolating and loading therapeutic agents into exosomes, enhancing their clinical application in various diseases while minimizing membrane damage.

€ 150.000
ERC Proof of...

High-Throughput Production of Extracellular Vesicles from Organoids under Rotating Motion

The project aims to develop a streamlined system for high-throughput production of extracellular vesicles (EVs) by integrating controlled cell configurations to enhance therapeutic potential.

€ 150.000
ERC Consolid...

Redesigning aortic endograft: enabling in-situ personalized aneurysm healing

EPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models.

€ 1.991.225
ERC Consolid...

Unravelling extracellular vesicle heterogeneity to inspire improved therapeutic RNA delivery systems

UNRAVEL aims to characterize extracellular vesicle subpopulations for enhanced RNA delivery, leading to the development of biomimetic synthetic RNA delivery systems to improve therapeutic applications.

€ 2.000.000

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients

reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.

€ 2.499.999
EIC Accelerator

Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients

Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.

€ 2.500.000
EIC Accelerator

TowArd demoCRatization Of ev-BAsed Therapies

EVerZom aims to revolutionize EV manufacturing with a patented scalable process, targeting GMP compliance and commercial production to lead the European market in clinical applications.

€ 1.700.000
Mkb-innovati...

Recombinant fibrinogen for extravascular support (EVS) after vein bypass grafting

Fibriant BV ontwikkelt een kosteneffectieve, recombinant fibrinogeenvariant voor extravasculaire steun bij bypass chirurgie om afsluiting van getransplanteerde aderen te verminderen.

€ 315.100
EIC Transition

Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell Culture

The Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials.

€ 2.488.750